Yves Cornellier, president and CEO of Alethia, said: “We are thankful for the continuous support of GO Capital, BDC Venture Capital and Epicentre Technologies. This new investment will be used to advance the development of Alethia’s portfolio of therapeutic monoclonal antibodies.
“These funds represent the first step towards the closing of a presently evolving series A round that will help bring our lead therapeutics into the clinic. Furthermore, this investment will allow us to further explore the potential of our programs to maximize their value for partnership opportunities.”